重组抗人CD4单抗(OKT4A) | Syd Labs PA007383.m2a
体内实验级重组抗人CD4单克隆抗体，小鼠IgG2a Kappa（克隆号：OKT4A，Syd Labs货号：PA007383.m2a），纯度>95%，适用于体外和体内研究。其不变区为小鼠Mouse IgG2a Kappa (mIgG2a或m2a)，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007383.m2a |
|---|---|
| 产品名称 | 重组抗人CD4单抗(OKT4A) | Syd Labs PA007383.m2a |
| 英文名 | In Vivo Grade Recombinant Anti-human CD4 Monoclonal Antibody (Clone: OKT4A), Mouse IgG2a Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | 分化簇4，leu-3，T4 |
| 概述 | Syd Labs提供重组小鼠IgG2a同型对照抗体和重组人IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | OKT4A |
| 同种型 | 小鼠 IgG2a kappa |
| 免疫源 | 抗人CD4单克隆抗体（克隆：OKT4A）在哺乳动物细胞中产生 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，无稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗人CD4单克隆抗体，小鼠 IgG2a Kappa(克隆号OKT4A)用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 1 个月，保存在2 至 8°C。 自收到之日起12个月，保存在-20 至 -70°C。 |
| 注意事项 | PA007383.m2a Syd Labs提供重组小鼠IgG2a同型对照抗体和重组人IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受人和非人灵长类CD4蛋白影响的生物学途径的测定。 |
文献
抗人CD4单克隆抗体，体内实验级重组，小鼠IgG2a Kappa (克隆号OKT4A)（In Vivo Grade Recombinant Anti-human CD4 Monoclonal Antibody (Clone: OKT4A), Mouse IgG2a Kappa，货号：PA007383.m2a Syd Labs）
重组 OKT4A 抗体可与人 CD4 蛋白（CD4 分子）结合，这是一种糖蛋白，也是 T 细胞受体（TCR）的共受体。CD4 蛋白表达于多种免疫细胞表面，如辅助性 T 细胞、单核细胞、巨噬细胞和树突状细胞。
抗人CD4单抗(OKT4A)部分引用文献:
1. Reduction of CD4+ T cells in vivo does not affect virus load in macaque elite controllers
Veazey, R. S., et al. J Virol. 2011 Jul;85(14):7454-9. PMID: 21593153
“A rhesus recombinant OKT4A antibody (anti-human CD4) was administered at 50 mg/kg intravenously to deplete CD4+ T cells in SIV-infected macaques. …Flow cytometry showed maximal depletion within one week, with significant loss of CD28+CD95− CD4+ T cells and SIV-specific responses, persisting for at least 8 weeks, without affecting viral load in elite controllers.”
2. Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A
Pulito, V. L., et al. J Immunol. 1996 Apr 15;156(8):2840-50. PMID: 8609403
“The OKT4A antibody (anti-human CD4) was studied for its immunosuppressive effects in nonhuman primate models of graft rejection and autoimmune disease. …Humanized gOKT4A-4 showed reduced immunogenicity compared to murine OKT4A, with computer modeling guiding humanization to retain binding activity, and preliminary clinical trials indicated no cytokine release syndrome or CD4+ T cell depletion.”
3. Infection of Brain Microglial Cells by Human Immunodeficiency Virus Type 1 Is CD4 Dependent
Jordan, C. A., et al. J Virol. 1991 Feb;65(2):736-42. PMID: 1702842
“The OKT4A antibody (anti-human CD4) was used to block HIV-1 infection in cultured microglial cells. …Pretreatment with OKT4A significantly reduced infection by HIV-1 strains AD87(M) and BaL, as measured by reverse transcriptase and p24 antigen levels, confirming CD4-dependent viral entry in brain-derived microglial cells via flow cytometry.”
4. Intracellular interaction of human immunodeficiency virus type 1 (ARV-2) envelope glycoprotein gp160 with CD4 blocks the movement and maturation of CD4 to the plasma membrane
Jabbar, M. A., et al. J Virol. 1990 Dec;64(12):6297-304. PMID: 2243395
“The OKT4 antibody (anti-human CD4), but not OKT4A (anti-human CD4), co-immunoprecipitated a specific gp160-CD4 complex in the endoplasmic reticulum of coexpressing cells. …OKT4A’s inability to bind this complex confirmed its distinct epitope specificity, demonstrating that gp160-CD4 interaction prevents CD4 maturation and surface expression, as assessed by flow cytometry.”
5. In vivo administration of anti-CD4 monoclonal antibody prolongs survival in longtailed macaques with experimental allergic encephalomyelitis
Rose, L. M., et al. J Neuroimmunol. 1987 Aug;16(1):1-12. PMID: 2445510
“The OKT4A antibody (anti-human CD4) was administered to three longtailed macaques with experimental allergic encephalomyelitis (EAE). …Treatment reversed CD4+ and CD8+ cell depletion, reduced brain lesion inflammation, and prolonged survival, suggesting OKT4A’s potential in treating human demyelinating diseases by modulating CD4+ T cell activity.”PA007385.m1